TWA
SWTX

TCI Wealth Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

TCI Wealth Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-132
Closed -$4K – 2647
2022
Q3 		$4K Hold
132
– – ﹤0.01% 1678
2022
Q2 		$3K Buy
132
+69
+110% +$2.52K ﹤0.01% 1903
2022
Q1 		$4K Sell
63
-77
-55% -$4.41K ﹤0.01% 1791
2021
Q4 		$9K Buy
140
+88
+169% +$5.82K ﹤0.01% 1282
2021
Q3 		$3K Sell
52
-29
-36% -$2.23K ﹤0.01% 2017
2021
Q2 		$7K Buy
81
+44
+119% +$3.34K ﹤0.01% 1244
2021
Q1 		$3K Buy
+37
New +$2.9K ﹤0.01% 1591

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCI Wealth Advisors's SWTX Position: Q4 2022 in Review

TCI Wealth Advisors sold out of SpringWorks Therapeutics (SWTX) in Q4 2022, closing a stake of 132 shares — an estimated $4K sold.

TCI Wealth Advisors first reported a position in SWTX in Q1 2021 and held it in 7 quarters. The position peaked at $9K in Q4 2021. 137 funds tracked by Wall St. Rank hold SWTX as of Q4 2022.

  • TCI Wealth Advisors reported no remaining SpringWorks Therapeutics position as of Q4 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 132 SpringWorks Therapeutics shares in Q4 2022, an estimated $4K.
  • TCI Wealth Advisors first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 7 quarters.
  • TCI Wealth Advisors's SpringWorks Therapeutics position peaked at $9K in Q4 2021.
  • 137 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2022.

Based on TCI Wealth Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.